aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows ...

On Friday, Cantor Fitzgerald reiterated its Overweight rating on aTyr Pharma (NASDAQ:ATYR) stock, with a focus on the company’s leading drug, Efzofitimod (Efzo; NRP2 modulator). The company, currently ...

Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma Fourth Quarter and Full Year 2024 Conference Call. At this time, all participants are in a listen-only mode. Later, we will ...

Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr” or the "Company”) ...

SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ:ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

ATYR PHARMA ($ATYR) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.18 per share, beating estimates of -$0.23 by $0.05 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $15 million in its fourth quarter. The San Diego-based company said it had a loss of 18 cents per share.

aTyr Pharma (NASDAQ: ATYR), with a market capitalization of $336 million, reported its fourth-quarter 2024 earnings, posting a smaller-than-expected loss and demonstrating significant progress in ...

SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the“Company”), a clinical stage biotechnology company engaged in the discovery and development of ...